TIS, developed by NanoString Technologies, was a clinical-grade assay, which can provides both quantitative and qualitative information about the tumor microenvironment (TME) and predicting response to anti-PD-1/PD-L1 agents (Seiwert et al., 2015). The gene discussed is CD274; the disease is neoplasm.